Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial
- 31 March 2006
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 54 (3), S112-S119
- https://doi.org/10.1016/j.jaad.2005.10.054
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- A Randomized Trial of Etanercept as Monotherapy for PsoriasisArchives of Dermatology, 2003
- Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trialArthritis & Rheumatism, 2003
- Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trialArthritis & Rheumatism, 2003
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- The effect of severe psoriasis on the quality of life of 369 patientsBritish Journal of Dermatology, 1995